RFS2000 (9-nitrocamptothecin) in advanced small cell lung cancer, a phase II study of the EORTC New Drug Development Group

CJA Punt, Maja de Jonge, S Monfardini, G Daugaard, W Fiedler, B Baron, D Lacombe, P Fumoleau

Research output: Contribution to journalArticleAcademicpeer-review

15 Citations (Scopus)
Original languageUndefined/Unknown
Pages (from-to)1332-1334
Number of pages3
JournalEuropean Journal of Cancer
Volume40
DOIs
Publication statusPublished - 2004

Research programs

  • EMC MM-03-86-08

Cite this